Article Sidebar
Published:
Nov 17, 2020Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Assessment of the therapeutic potential of anti-miR 24 and anti-miR 34 in cardiac diseases
Abstract
Purpose: To study the therapeutic effects of anti-miR-24 and anti-miR-34 in cardiac diseases
Methods: H9c2 rat cardiomyocyte cell lines were transfected with the synthetic oligonucleotides antimiR-24 and anti-miR-34 which reduced the expressions of miR-24 and miR-34. Proliferation assay, real time-polymerase chain reaction (RT-PCR) and immunoblotting were carried out to determine the effect of the transfections on cardiomyocyte proliferation, expressions of miR-24 and miR-34, as well as expressions of the target genes, TGF-β1 and E2F3.
Results: The proliferation ability of the transfected cells was decreased significantly, relative to negative control. In contrast, percentage apoptosis was higher in the negative control group than in transfected cells. The expression profiles of anti-miR-24 and anti-miR-34 were significantly reduced, when compared to negative control. These results were further confirmed using immunoblot which revealed that the expression of the target genes, TGF-β1 and E2F3, were upregulated in the transfected cells.
Conclusion: These results suggest that the synthetic oligonucleotides (anti-miR-24 and anti-miR-34) might be useful in developing therapeutic drug targets for cardiac diseases by suppressing the expressions of miR-24 and miR-34.
Keywords: H9c2rat cardiomyocyte miRNA, Anti-miR-24, Anti-miR-34, Cardiac diseases
